Houston universities earn top marks for research and student opportunity

top of class

Five Houston universities were named among the Carnegie Foundation's top tier of research institutions. Photo courtesy UH.

The American Council on Education and the Carnegie Foundation for the Advancement of Teaching recently released its new Research Activity Designations, which named several Houston universities to its Very High Research Spending and Doctorate Production, or R1, tier.

The R1 status means that universities meet $50 million in total annual research spending and 70 research doctorates awarded annually. This year, 187 institutions were given the designation, according to the Carnegie Foundation.

The 2025 categorizations were made using an updated methodology to be "more reflective of the wide range of higher education institutions across America and how well they serve their students," according to a release. Until now, research activity was included in the foundations' Basic Classifications. This year was the first year the Research Activity Designations were published separately.

“These updates to the Carnegie Classifications are the first step to bring a decades-old system into the 21st century. We are expanding our recognition of the range of ways colleges and universities engage in research and development,” Timothy F.C. Knowles, president of the Carnegie Foundation, said in the release. “And we are taking the guesswork out of what it takes to be recognized as an R1 institution. Over time, this will be good for the sector, for scholarship, for policymakers and for students.”

Here are the Houston institutions to receive the R1 designation:

  • Baylor College of Medicine
  • Rice University
  • The University of Texas Health Science Center at Houston
  • The University of Texas MD Anderson Cancer Center
  • University of Houston

The foundation also released new Student Access and Earnings Classifications, which honor colleges that serve a student body representative of their local community and help achieve competitive post-graduation earnings.

UH was the only Houston college to earn the Opportunity College & University – Higher Access, Higher Earnings (OCU) designation, and was one of only 21 universities in the country to earn it in addition to the R1 status for research.

“Maintaining our new Opportunity College and University designation reflects our unwavering commitment to access and economic mobility for all students, while our R1 research status speaks to the strength of our faculty and the transformative scholarship happening on our campus,” UH president Renu Khator said in a news release.

Just 16 percent of U.S. colleges and universities received the OCU designation. The classification comes from publicly available data from the U.S. Department of Education’s College Scorecard, the Integrated Postsecondary Education Data System and the U.S. Census Bureau. The classification considers the percentage of Pell Grant recipients, the number of underrepresented students enrolled, the median undergraduate earnings eight years after enrollment and other factors.

“These recognitions help tell the full story of our institution’s impact,” Diane Z. Chase, senior vice president for academic affairs and provost at UH, added in the release. “UH is a powerhouse for ideas, innovation and opportunity. We are changing lives through discovery, access and economic mobility—not only for our students, but for the communities we serve.”

Comparatively, Rice earned a Lower Access, Higher Earnings designation. The other Houston universities were not classified in the Student Access and Earnings Classifications.

In 2024, Rice University was one of 25 U.S. colleges and universities to receive the first Carnegie Leadership for Public Purpose Classification. The classification highlights colleges that have committed to “campus-wide efforts to advance leadership in pursuit of public goods like justice, equity, diversity and liberty.” Read more here.

From Your Site Articles
Texas doctors and researchers received millions for their transformational work in cancer prevention and treatment. Getty Images

A Texas organization has doled out millions to Houston cancer-fighting professionals

granted

Researchers at medical institutions across the state have something to celebrate. The Cancer Prevention and Research Institute of Texas has made 71 grants this week to cancer-fighting organizations that total a near $136 million.

"CPRIT's priorities of pediatric cancer research and cancers of significance to Texans highlight this large slate of awards," says Wayne Roberts, CPRIT CEO, in a release. "Investments are made across the cancer research and prevention continuum in Texas unlike any other state in the country."

New to the awards this time around is the Collaborative Action Program for Liver Cancer, which has been claimed by Baylor College of Medicine's Hashem B. El-Serag.

"Texas has the highest incidence rates of hepatocellular cancer in the nation," El-Serag says in a release from BCM. "Our CPRIT funded Center will house infrastructure to support and enhance research collaborations among liver cancer researchers; to educate providers, researchers and the general public on best practices and opportunities to reduce the burden of liver cancer; and to engage private and public entities in policy initiatives."

Houston organizations also received recruitment awards, which reward Texas organizations for bringing in great minds from across the world. According to the release, CPRIT has brought in a total of 181 scholars and 13 companies to the Lone Star State.

Of the 71 grants, 58 represent academic research, 10 prevention, and three product development research. Here are the ones awarded to Houston organizations.

The University of Texas MD Anderson Cancer Center

  • $900,000 granted for Shao-Cung Sun's research in regulation of CD8 T cell responses in antitumor immunity (Individual Investigator Research Award)
  • $897,483 granted for Alemayehu A. Gorfe's research in characterization and optimization of novel allosteric KRAS inhibitors (Individual Investigator Research Award)
  • $3 million granted for Hashem B. El-Serag's research at The Texas Collaborative Center for Hepatocellular Cancer (Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center Award)
  • $2.46 million to Jessica Hwang for patient-centered liver cancer prevention in the Houston community (Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Investigator-Initiated Research Awards)
  • $3.51 million for Kevin McBride's Recombinant Antibody Production Core at Science Park
  • $199,804 granted for Andrea Viale's epithelial memory of resolved inflammation as a driver of pancreatic cancer progression (High Impact High Risk Award)
  • $6 million for the recruitment of Christopher Flowers, M.D. (Recruitment of Established Investigator Awards)
  • $2 million for the recruitment of Kevin Nead, MD, MPhil (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Alison Taylor, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Mackenzie Wehner, MD, MPhil (Recruitment of First-Time, Tenure-Track Faculty Members Awards)

Baylor College of Medicine

  • $5.38 million granted for Steven J. Ludtke's new capabilities for cancer research in the TMC CryoEM Cores (Core Facility Support Awards)
  • $1.35 million granted for Bryan M. Burt's novel endoscope-cleaning port for minimally invasive cancer surgery (Early Translational Research Awards)
  • $199,500 granted for Yohannes T. Ghebre's Topical Esomeprazole for Radiation-induced Dermatitis (High Impact High Risk Award)
  • $199,920 granted for Robin Parihar's targeting of cancer associated fibroblasts with anti-IL-11-secreting CAR T cells (High Impact High Risk Award)
  • $2 million for the recruitment of Umesh Jadhav, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Stanley Lee, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Ang Li, MD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $1.29 million for Jane R. Montealegre's expansion of "a Community Network for Cancer Prevention to Increase HPV Vaccine Uptake and Tobacco Prevention in a Medically Underserved Pediatric Population"

Texas Medical Center

  • $5.44 million granted for William McKeon's Business-Driven Accelerator for Cancer Therapeutics (Core Facility Support Awards)

The University of Texas Health Science Center at Houston

  • $5.95 million granted for Zhiqiang An's Advanced Cancer Antibody Drug Modalities Core Facility (Core Facility Support Awards)
  • $2 million granted for Qingyun Liu's discovery and development of novel peptibody-drug conjugate for treating cancers of the digestive system (Early Translational Research Awards)
  • $199,998 granted for Leng Han's expression landscape and biomedical significance of transfer RNAs in cancer (High Impact High Risk Award)
  • $2 million for Lara S. Savas' Salud en Mis Manos that delivers "Evidence-Based Breast & Cervical Cancer Prevention Services to Latinas in Underserved Texas South and Gulf Coast Communities"

The University of Texas Medical Branch at Galveston

  • $3.55 million granted for William K. Russell's A Targeted Proteomics and Metabolomics Mass Spectrometry Core Facility at the University of Texas Medical Branch at Galveston (Core Facility Support Awards)
  • $199,996 granted for Brendan Prideaux's novel cellular-level imaging approach to assess payload drug distribution in tumors following administration of targeted drug delivery systems (High Impact High Risk Award)
  • $200,000 granted for Casey W. Wright's targeting ARNT and RBFOX2 alternative splicing as a novel treatment modality in lymphoid malignancies (High Impact High Risk Award)

The Methodist Hospital Research Institute

  • $200,000 granted for Robert Rostomily's development of a mini-pig glioma model and validation of human clinical relevance (High Impact High Risk Award)

Texas Southern University

  • $200,000 for Song Gao's alleviating SN-38-induced late-onset diarrhea by preserving local UGTs in the colon (High Impact High Risk Award)

University of Houston

  • $200,000 granted for Sergey S. Shevkoplyas' Novel High-Throughput Microfluidic Device for Isolating T-cells Directly from Whole Blood to Simplify Manufacturing of Cellular Therapies (High Impact High Risk Award)

Rice University

  • $2 million for the recruitment of Jiaozhi (George) Lu, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $1.67 million for the recruitment of Vicky Yao, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)

The Rose

  • $2 million for Bernice Joseph's Empower Her To Care Expansion

Legacy Community Health Services

  • $999,276 for Charlene Flash's "Increasing Breast and Colorectal Cancer Screening Rates for the Medically Underserved using Population Health Strategies at a Multi-County FQHC"
The design and construction team has been announced for TMC3. Courtesy of Elkus Manfredi Architects

Texas Medical Center reveals new details and renderings for its TMC3 campus

Coming to hou in 2022

The Texas Medical Center just announced the dream team of architects and designers that are making TMC3 into a reality.

Elkus Manfredi Architects, Transwestern, and Vaughn Construction are the three companies that will serve as the architectural and development team for the 37-acre research campus. TMC3's founding institutions — TMC, Baylor College of Medicine, Texas A&M University Health Science Center, The University of Texas Health Science Center at Houston, and The University of Texas MD Anderson Cancer Center — decided on the three entities.

"Texas Medical Center is eager to move forward with a bold, imaginative and dynamic new design vision for the TMC3 Master Plan," says TMC CEO and president, Bill McKeon, in a press release. "With the combined talents of Elkus Manfredi Architects, Transwestern, and Vaughn Construction on-board, I couldn't be more confident that this dream team will flawlessly execute the totality of the project's vision and fulfill its mission to bring together leading researchers and top-tiered expertise from the private sector to create the number one biotechnology and bioscience innovation center in the entire world."

TMC3 was first announced just over a year ago and is planned to open in 2022. The campus will incorporate research facilities, retail space, residential plans, a hotel and conference center, and green space. Parking will be underground to optimize surface area.

Design in mind

The 37-acre research campus will be interconnected by a DNA helix outdoor promenade.

Courtesy of Elkus Manfredi Architects

From a design perspective, the key element will be a DNA helix-shape that looks like a necklace chain that connects the campus.

"Our idea was to expand on the DNA design concept and create a series of spaces that would elongate the strand all the way north to the historic core of the Texas Medical Center and south to the new development by UTHealth and MD Anderson in order to create more opportunity for connections and collisions," says Elkus Manfredi Architects CEO and founding principal, David Manfredi, in the release. "We're implementing the connective tissue between all these places and establishing opportunities for unplanned interactions. Science, technology, medicine, discovery and innovation are all about making connections, and we are building a space for institutions, industry and startups to interact."

Manfredi's firm is responsible for a few other iconic medical facilities, such as the original Broad Institute of MIT and Harvard and The Stanley Building at the Broad Institute in Cambridge, Massachusetts, and the New York Genome Center.

"We want to create spaces that attract talent," Manfredi says in the release. "You can attract talent with great colleagues, research and facilities, but if you don't have a great social environment for people to live, learn, and play, people move on. We are creating a place where people will want to be because they're constantly stimulated – whether it's breakfast at the local coffee shop, or a volleyball league in the afternoon, or working in a central lab and the person next to them is doing something intersects with their own research."

Growing partner institutions

TMC3 Collaborative will be a centrally located building on the campus that is designed to host gatherings and share space with industry leaders.

Courtesy of Elkus Manfredi Architects

While a big portion of the attraction in the new campus is this multi-purposeful and connective space, the project opens doors for the five partner institutions. For Baylor College of Medicine, TMC3 means an expansion of its facilities and an increased footprint for Baylor St. Luke's Medical Center's McNair Campus. The second tower of the hospital will be right at TMC3's eastern edge.

"The selection of a development team is an important milestone for the TMC3 project," says Paul Klotman, president, CEO and executive dean of Baylor College of Medicine, in the release. "The project itself is a huge step in developing the biotech industry in Houston. At Baylor, we look forward to working closely with TMC leaders, as well as those of the other anchor institutions, in making this project a reality."

Additionally, the Texas A&M Health Science Center research building — led by Carrie L. Byington, M.D — on the north end adjacent to BCM's building and the hotel and conference center. On the south side of the campus, MD Anderson and UTHealth will each develop new research facilities that will connect to the existing University of Texas Research Park that is directly to the south of the campus. UT Research Park will be connected to TMC3 via a new skybridge.

The release also describes a central building dubbed TMC3 Collaborative that will create collaborative research space for industry partners. The first level of the building will be an open atrium for gatherings and have food and beverage concepts.

"When TMC3 opens in 2022, Texas Medical Center will officially plant a tangible flag that signals its arrival as the Third Coast for life sciences for the foreseeable future," McKeon says in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."

7 Houston neighbors named to U.S. News' best places to live in 2026

Living Well

Several Houston suburbs have been crowned the best places to live in the U.S. for 2026, according to U.S. News & World Report. Sugar Land is the highest-ranked city in the Houston metro, and it ranks as the 10th best place to live in the country.

The annual list of Best Places to Live in the U.S. is designed to help readers make the most informed decisions when choosing where to settle down, using data from sources such as the U.S. Census Bureau, Department of Commerce, the Federal Reserve and the Bureau for Economic Analysis, as well as state and local sources.

For the 2026-2027 rankings, U.S. News featured 250 U.S. cities and ranked them across four livability indexes — quality of life, value, desirability, and job market — weighted by importance based on survey results of approximately 500 Americans. The rankings were also broken down state-by-state, as well as the best big, medium, and small cities overall.

Sugar Land is the No. 4 best places to live in Texas, and it soared into the No. 10 spot overall in the nation after ranking 16th last year. Sugar Land also ranks as the fourth-best mid-sized city to live in America for 2026-2027.

According to U.S. News, Sugar Land's median household income is far higher than the national average. Residents make $140,511 per year, while the average American household income is only $83,181.

Additionally, the $431,815 median home value in Sugar Land is also far greater than the $359,870 national average.

After ranking in the top 10 in the 2025 report, League City and Pearland now both rank outside the national top 10 for 2026. League City slipped from No. 6 to No. 13 this year, while Pearland dropped from No. 3 nationwide to No. 16.

These three Houston suburbs also boast highly desirable job markets for potential newcomers or current residents that want to start or change their career.

Houston proper, however, remains outside of the top 250 and is the 327th best place to live in the U.S., and it's the 60th best place to live in Texas.

Other cities in the greater Houston area that ranked among the top 100 include:

  • No. 28 – The Woodlands
  • No. 38 – Katy
  • No. 61 – Missouri City
  • No. 82 – Spring

The Lone Star State had a "strong showing" in the overall top 10 thanks to its "high affordability scores," a release said. Besides Sugar Land, three more popular Texas suburbs made the cut: Leander (No. 8) outside Austin and Dallas-Fort Worth suburbs Flower Mound (No. 3) and Frisco (No. 9).

"As prices of everyday goods continue to rise, consumers are considering affordability as a top priority when choosing a place to live," said U.S. News consumer lending analyst Erika Giovanetti. "While U.S. News’ consumer survey indicated that quality of life and affordability were close in importance, cost-of-living concerns resulted in many Americans putting what they can afford above their aspirations."

---

This article originally appeared on CultureMap.com.

View All Listings